Superbag are superlucky!

Public support for antibiotics research couldn’t come at a more crucial time. The WHO warned last month that bacterial resistance may turn common infections and minor injuries into killers within this century. In the U.S., at least 2 million people become infected with drug-resistant bacteria each year, leading to at least 23,000 deaths, according to the Centers for Disease Control and Prevention.

There’s an economic cost, too: about $20 billion in the U.S. alone, Edward Nash, a New York-based analyst for Cowen & Co., wrote in a report to investors this month. The global antibiotics market may be valued at about $44.7 billion in 2016, Nash said.

 

AstraZeneca’s most advanced experimental project is a combination of ceftazidime and avibactam called CAZ-AVI.

 

http://www.bloomberg.com/news/2014-05-22/superbug-researchers-wait-on-future-of-astrazeneca-drugs.html?cmpid=yhoo